254 related articles for article (PubMed ID: 27151773)
1. Tolerability of Therapies Recommended for the Treatment of Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer.
Ohno S
Clin Breast Cancer; 2016 Aug; 16(4):238-46. PubMed ID: 27151773
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant treatment in hormone receptor-positive early breast cancer: New approaches of endocrine therapy.
Nardin S; Ruelle T; Giannubilo I; Del Mastro L
Tumori; 2024 Jun; 110(3):162-167. PubMed ID: 38112006
[TBL] [Abstract][Full Text] [Related]
3. Endocrine therapies in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative, pretreated, advanced breast cancer: A network meta-analysis.
Lee CH; Kang YN; Ho CL; Lin C; Chen PH; Wu YY; Huang TC
Medicine (Baltimore); 2020 Mar; 99(13):e19618. PubMed ID: 32221087
[TBL] [Abstract][Full Text] [Related]
4. Endocrine Therapy in the Current Management of Postmenopausal Estrogen Receptor-Positive Metastatic Breast Cancer.
Kaklamani VG; Gradishar WJ
Oncologist; 2017 May; 22(5):507-517. PubMed ID: 28314835
[TBL] [Abstract][Full Text] [Related]
5. The sequential use of endocrine treatment for advanced breast cancer: where are we?
Barrios C; Forbes JF; Jonat W; Conte P; Gradishar W; Buzdar A; Gelmon K; Gnant M; Bonneterre J; Toi M; Hudis C; Robertson JF
Ann Oncol; 2012 Jun; 23(6):1378-86. PubMed ID: 22317766
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of fulvestrant 500 mg in Chinese postmenopausal women with advanced/recurrent breast cancer and factors associated with prolonged time-to-treatment failure: A retrospective case series.
Huang J; Huang P; Shao XY; Sun Y; Lei L; Lou CJ; Ye WW; Chen JQ; Cao WM; Huang Y; Zheng YB; Wang XJ; Chen ZH
Medicine (Baltimore); 2020 Jul; 99(29):e20821. PubMed ID: 32702824
[TBL] [Abstract][Full Text] [Related]
7. Role of aromatase inhibitors in breast cancer.
Carpenter R; Miller WR
Br J Cancer; 2005 Aug; 93 Suppl 1(Suppl 1):S1-5. PubMed ID: 16100519
[TBL] [Abstract][Full Text] [Related]
8. Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast Cancer.
Andrahennadi S; Sami A; Manna M; Pauls M; Ahmed S
Curr Oncol; 2021 May; 28(3):1803-1822. PubMed ID: 34064867
[No Abstract] [Full Text] [Related]
9. Next generation selective estrogen receptor degraders in postmenopausal women with advanced-stage hormone receptors-positive, HER2-negative breast cancer.
Sharaf B; Hajahjeh A; Bani Hani H; Abdel-Razeq H
Front Oncol; 2024; 14():1385577. PubMed ID: 38800404
[TBL] [Abstract][Full Text] [Related]
10. Managing aromatase inhibitors in breast cancer survivors: not just for oncologists.
Files JA; Ko MG; Pruthi S
Mayo Clin Proc; 2010 Jun; 85(6):560-6; quiz 566. PubMed ID: 20511486
[TBL] [Abstract][Full Text] [Related]
11. Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline.
Rugo HS; Rumble RB; Macrae E; Barton DL; Connolly HK; Dickler MN; Fallowfield L; Fowble B; Ingle JN; Jahanzeb M; Johnston SR; Korde LA; Khatcheressian JL; Mehta RS; Muss HB; Burstein HJ
J Clin Oncol; 2016 Sep; 34(25):3069-103. PubMed ID: 27217461
[TBL] [Abstract][Full Text] [Related]
12. TransCONFIRM: Identification of a Genetic Signature of Response to Fulvestrant in Advanced Hormone Receptor-Positive Breast Cancer.
Jeselsohn R; Barry WT; Migliaccio I; Biagioni C; Zhao J; De Tribolet-Hardy J; Guarducci C; Bonechi M; Laing N; Winer EP; Brown M; Leo AD; Malorni L
Clin Cancer Res; 2016 Dec; 22(23):5755-5764. PubMed ID: 27185372
[TBL] [Abstract][Full Text] [Related]
13. Improving Response to Hormone Therapy in Breast Cancer: New Targets, New Therapeutic Options.
Rugo HS; Vidula N; Ma C
Am Soc Clin Oncol Educ Book; 2016; 35():e40-54. PubMed ID: 27249746
[TBL] [Abstract][Full Text] [Related]
14. Profile of palbociclib in the treatment of metastatic breast cancer.
Ehab M; Elbaz M
Breast Cancer (Dove Med Press); 2016; 8():83-91. PubMed ID: 27274308
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneous estrogen receptor expression in circulating tumor cells suggests diverse mechanisms of fulvestrant resistance.
Paoletti C; Larios JM; Muñiz MC; Aung K; Cannell EM; Darga EP; Kidwell KM; Thomas DG; Tokudome N; Brown ME; Connelly MC; Chianese DA; Schott AF; Henry NL; Rae JM; Hayes DF
Mol Oncol; 2016 Aug; 10(7):1078-85. PubMed ID: 27178224
[TBL] [Abstract][Full Text] [Related]
16. Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3).
Verma S; Bartlett CH; Schnell P; DeMichele AM; Loi S; Ro J; Colleoni M; Iwata H; Harbeck N; Cristofanilli M; Zhang K; Thiele A; Turner NC; Rugo HS
Oncologist; 2016 Oct; 21(10):1165-1175. PubMed ID: 27368881
[TBL] [Abstract][Full Text] [Related]
17. [Combination Therapy of Molecular-Targeted Drugs for Breast Cancer -- Their Potential in the Future].
Okano M; Ohtake T; Saji S
Gan To Kagaku Ryoho; 2016 Apr; 43(4):398-403. PubMed ID: 27220784
[TBL] [Abstract][Full Text] [Related]
18. Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence.
Chirgwin JH; Giobbie-Hurder A; Coates AS; Price KN; Ejlertsen B; Debled M; Gelber RD; Goldhirsch A; Smith I; Rabaglio M; Forbes JF; Neven P; Láng I; Colleoni M; Thürlimann B
J Clin Oncol; 2016 Jul; 34(21):2452-9. PubMed ID: 27217455
[TBL] [Abstract][Full Text] [Related]
19. ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling.
Gelsomino L; Gu G; Rechoum Y; Beyer AR; Pejerrey SM; Tsimelzon A; Wang T; Huffman K; Ludlow A; Andò S; Fuqua SAW
Breast Cancer Res Treat; 2016 Jun; 157(2):253-265. PubMed ID: 27178332
[TBL] [Abstract][Full Text] [Related]
20. Network Meta-Analysis of the Effectiveness of Neoadjuvant Endocrine Therapy for Postmenopausal, HR-Positive Breast Cancer.
Wang W; Liu C; Zhou W; Xia T; Xie H; Wang S
Sci Rep; 2016 May; 6():25615. PubMed ID: 27174543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
